1544740-01-3

Upstream product

• 1544740-00-2 1-((5-bromo-4-(trifluoromethyl)pyridin-2-yl)oxy)-2-methylpropan-2-ol 
• 1544739-26-5 (5aR,6S,6aS)-ethyl 3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-99-2 2-methyl-1-((4-(trifluoromethyl)pyridin-2-yl)oxy)propan-2-ol 
• 1544739-98-1 ethyl 2-((4-(trifluoromethyl) pyridin-2-yl)oxy)acetate 
• 50650-59-4 2-hydroxy-4-(trifluoromethyl)-pyridine 
• 81565-18-6 2-chloro-4-trifluoromethyl pyridine 

Downstream Products

• 1544739-97-0 (5aR,6S,6aS)-3-((3-(6-(2-hydroxy-2-methylpropoxy)-4-(trifluoromethyl)pyridin-3-yl)benzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 

Relevant academic research and scientific papers

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.